Advertisement

Reactions Weekly

, Volume 1732, Issue 1, pp 155–155 | Cite as

Docetaxel/epirubicin

Febrile neutropenia and neutropenic typhlitis: 3 case reports
Case report
  • 19 Downloads
Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

  • * death

  • * life-threatening

  • * hospitalisation

  • * disability

  • * congenital anomaly

  • * other medically important event

In a study of 150 patients, 3 patients (1 woman) [not all sexes stated] aged 41−56 years were described, who developed febrile neutropenia and neutropenic typhlitis following treatment with docetaxel and epirubicin for breast cancer. Of these three patients, the 42-year-old woman also experienced drug toxicity and died due to neutropenic typhlitis.

Patient 1: The 42-year-old woman, who had breast cancer stage II, was initiated on the first course of chemotherapy with IV docetaxel 75 mg/m2 and IV epirubicin 75 mg/m2every three weeks. Eight days after receiving the first course, she presented to the emergency room due to diverse symptoms. She presented with grade 4 febrile neutropenia despite receiving prophylactic therapy with pegfilgrastim. Her symptoms included grade 3...

Reference

  1. Sim S, et al. Pharmacogenetic impact of docetaxel on neoadjuvant treatment of breast cancer patients. Pharmacogenomics 19: 1259-1268, No. 16, Nov 2018. Available from: URL: http://doi.org/10.2217/pgs-2018-0080 - SwedenCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Personalised recommendations